Company intelligence / Profile preview

ARTMS

Vancouver, British Columbia, Canadaartms-strategy.com ↗

Ownership: Private
Development stage: Commercial

Overview

ARTMS developed the QUANTM Irradiation System™, enabling high-yield, GMP-quality cyclotron production of key medical isotopes such as zirconium‑89, gallium‑68, technetium‑99m, and copper‑64. These isotopes are used in diagnostic radiopharmaceuticals for oncology, cardiology, and neurology. The company’s technology is installed globally and has improved access to critical diagnostic scans by decentralizing isotope supply chains.

Therapeutic areas: OncologyCardiovascularNeurology
Modalities: RadiopharmaceuticalDevice (cyclotron-based isotope production system)
Industry: Medical Imaging

Partnerships

TRIUMF laboratory collaborationMajor manufacturing networks using QIS™ systemAcademic collaborations with Queen’s University and ABB Zurich via key personnel backgrounds

Beyond the preview

Go deeper on ARTMS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARTMS.

Explore the full profile